Quarterly report pursuant to Section 13 or 15(d)

Note 2 - Liquidity (Details Textual)

v3.22.2.2
Note 2 - Liquidity (Details Textual) - USD ($)
Aug. 30, 2022
Aug. 11, 2022
Aug. 03, 2022
Jul. 01, 2022
Apr. 12, 2022
Oct. 11, 2022
Sep. 30, 2022
Apr. 10, 2022
Rights Offering, Shares Authorized (in shares)     35,000          
Shares Issued, Price Per Share (in dollars per share)     $ 1,000          
Units Issued During Period, Units, New Issues (in shares) 10,423              
Proceeds from Issuance or Sale of Equity, Total $ 6,173,000              
Class of Warrant or Right, Outstanding (in shares)             23,582,230  
Payments to Fund Clinical Research Trial 963,270              
Payments of Stock Issuance Costs $ 963,270              
API Development Funding and Access Agreement [Member]                
Development Agreement, Reimbursement Amount             $ 1,850,000  
Development Agreement, Reimbursement Proceeds   $ 800,000            
Unit Warrants [Member]                
Class of Warrant or Right, Outstanding (in shares) 1              
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) 2,222              
Class of Warrant or Right, Purchase Price of Stock (in dollars per share) $ 0.45              
Class of Warrants or Rights, Warrant Proceeds if Exercised $ 11,600,000              
Warrants and Rights Outstanding, Term (Year) 5 years              
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) $ 0.50              
Series I Preferred Stock [Member]                
Convertible Preferred Stock, Shares Issued upon Conversion (in shares) 2,222              
Units Sold in Exchange for Series D Preferred Stock [Member]                
Units Issued During Period, Units, New Issues (in shares) 4,250              
Purchase Agreement [Member] | Vice Chairman of Board of Directors [Member]                
Debt Instrument, Face Amount               $ 2,500,000
Proceeds from Issuance of Long-Term Debt, Total       $ 1,000,000.0 $ 1,500,000      
Debt Instrument, Interest Rate, Stated Percentage               8.00%
CRG Loan Agreement, Texas Case [Member]                
Litigation Settlement, Amount Awarded to Other Party $ 2,600,000              
Loss Contingency Accrual, Ending Balance             $ 3,300,000  
CRG Loan Agreement, Texas Case [Member] | Subsequent Event [Member]                
Loss Contingencies, Interest Rate           18.00%